Iambic Therapeutics, Inc. Common Stock (IAM NASDAQ) stock market data APIs
$15.5026
-0.62(-4%)
as of November 11, 2026
Try our APIs with
free plan!
Iambic Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
Prev. Close
15.5026
Open
14.8806
High
15.8694
Low
14.014
52 wk Range
9.6-25
Market Cap
729 M
Shares Outstanding
47 401 K
Revenue
18 251 K
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Iambic Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Iambic Therapeutics, Inc. Common Stock Fundamental Data
Iambic Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue: 18 251 K
- EBITDA: -98 806 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Iambic Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-06-30
- EPS/Forecast: -5.8787
Get Iambic Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Iambic Therapeutics, Inc. Common Stock News
New
Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus
The S&P 500 Health Care Sector Index (XLV) gained 3% for the week.The top S&P 500 healthcare gainers and losers for the past week are as follows:TOP FIVE GAINERS: * Idexx Laboratories (IDXX [https:...
Iambic Therapeutics (IAM) Joins The Nasdaq Composite, Is The Stock Already Pricey?
Iambic Therapeutics (IAM) was just added to the Nasdaq Composite Index after a busy October that included its US$150 million IPO and a US$184.6 million shelf registration. The recent Nasdaq Composite...
Another Biotech IPO Pops on Rough Day for Broader Market
It's another risk-off day for the broader market, with tech taking another tumble, thanks to a continued slide for semiconductor stocks. Continue Reading
Cathie Wood-Backed Biotech IPO Pops in Debut
The IPO market may be in a bit of a slump as investors wait for Anthropic to finally file officially for a stock sale. Continue Reading
Get Iambic Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.